Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.37 |
| ▸ | CA2 | P00918 | 8/20 | 0.37 |
| ▸ | CA7 | P43166 | 8/20 | 0.37 |
| ▸ | CA4 | P22748 | 7/20 | 0.37 |
| ▸ | CA12 | O43570 | 7/20 | 0.37 |
| ▸ | CA6 | P23280 | 7/20 | 0.37 |
| ▸ | CA5A | P35218 | 7/20 | 0.37 |
| ▸ | CA9 | Q16790 | 7/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929807 | 0.84 | CA2 (0.41) | CA1CA2CA7CA4CA12 | |
| SCHEMBL7733315 | 0.81 | ALDH1A1 (0.38) | ALDH1A1TDP2NSD2HSP90AA1PAX8 | |
| SCHEMBL1523492 | 0.74 | CD44 (0.48) | CA1CA2CA7CA4CA12 | |
| SCHEMBL28865694 | 0.72 | ALDH1A1 (0.33) | CA1CA2CA7CA4CA12 | |
| SCHEMBL2933802 | 0.72 | RAB9A (0.47) | CA1CA2CA7CA12CA6 | |
| Sulfuric Acid SCHEMBL2386170 | 0.71 | ALDH1A1 (0.41) | ALDH1A1TDP2NSD2HSP90AA1PAX8 | |
| Sulfuric Acid SCHEMBL17847416 | 0.71 | ALDH1A1 (0.41) | ALDH1A1TDP2NSD2HSP90AA1PAX8 | |
| SCHEMBL7099141 | 0.71 | CYP3A4 (0.39) | ALDH1A1TDP2NSD2HSP90AA1PAX8 | |
| SCHEMBL11579509 | 0.70 | ALDH1A1 (0.42) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL10867140 | 0.70 | ALDH1A1 (0.40) | CA1CA2CA7CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524841-B2 | 4,4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| CN-100360521-C | 4,4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LTD (JP) | 2008-01-09 | — | — | CN | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| CN-1665804-A | 4, 4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LTD (JP) | 2005-09-07 | — | — | CN | disclosed |
| CN-1659161-A | Piperidine derivatives having CCR3 antagonism | TEIJIN LTD (JP) | 2005-08-24 | — | — | CN | disclosed |
| EP-1505067-A1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-09 | — | — | EP | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | CA1 3209/4885CA2 1068/4885CA7 1930/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | CA1 1903/4885CA2 1071/4885CA7 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.